Modulation of CD28 expression with anti–tumor necrosis factor α therapy in rheumatoid arthritis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective: The immune system of patients with rheumatoid arthritis (RA) is characterized by the accumulation of CD4+ T cells deficient in CD28 expression and the up‐regulation of tumor necrosis factor α (TNFα). Previous in vitro studies have shown that TNFα induces transcriptional silencing of the CD28 gene. Because reduced expression of CD28 in T cells compromises immunocompetence, we examined whether CD28 expression is reduced in patients with RA in vivo and whether the reduction is related to TNFα. Methods: Patients with RA and age‐matched individuals were recruited. Peripheral blood mononuclear cells were stained for CD3, CD4, CD8, CD28, TNF receptor I (TNFRI), and TNFRII, and analyzed by quantitative flow cytometry. The number of CD28 and TNFR molecules was monitored in a subgroup of patients with RA undergoing treatment with anti‐TNFα. Results: In addition to higher frequencies of CD28 null T cells, patients with RA had significantly reduced numbers of CD28 and TNFRI molecules on CD4+,CD28+ T cells. Normal expression could be restored in vitro by overnight culture, suggesting that CD28 in patients was modulated by exogenous factors. In contrast, treatment with TNFα in vitro resulted in further down‐regulation. CD28 expression was normalized in patients undergoing TNFα‐neutralizing therapy. Conclusion: Overproduction of TNFα in RA induces a global down‐regulation of CD28 in CD4+ T cells and may cause reduced sensitivity to costimulatory signals in T cell responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717
CD28-mediated co-stimulation: a quantitative support for TCR signalling.
Acuto, O., & Michel, F. (2003) · Nature Reviews Immunology · doi:10.1038/nri1248 · Cited by 775
Schmidt, D., Goronzy, J. J., & Weyand, C. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118638 · Cited by 482
Self-citationGoronzy, J. J., Fulbright, J. W., Crowson, C. S., Poland, G. A., O'Fallon, W. M., & Weyand, C. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12182-12187.2001 · Cited by 402
Self-citationDown-Regulation of CD28 Expression by TNF-α
Bryl, E., Vallejo, A. N., Weyand, C. M., & Goronzy, J. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.6.3231 · Cited by 264
Self-citationVallejo, A. N., Weyand, C. M., & Goronzy, J. J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.01.002 · Cited by 223
Self-citationDe Tena, J. G., Manzano, L., Leal, J. C., Antonio, E. S., Sualdea, V., & Álvarez-Mon, M. (2004) · Journal of Clinical Immunology · doi:10.1023/b:joci.0000019784.20191.7f · Cited by 59
Cited by
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
The interplay between immunosenescence and age-related diseases
Barbé-Tuana, F., Funchal, G., Schmitz, C. R. R., Maurmann, R. M., & Bauer, M. E. (2020) · Seminars in Immunopathology · doi:10.1007/s00281-020-00806-z · Cited by 384
Successful and Maladaptive T Cell Aging
Goronzy, J. J., & Weyand, C. M. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.010 · Cited by 362
“This increased turnover does not derive from truly naive cells, but from CD95+CD45RA+CD28+ T cells that represent reverted memory cells (Pulko et al., 2016), memory stem cells (Fuertes Marraco et al., 2015), or cells that have undergone extensive homeostatic proliferation reminiscent of murine virtual memory cells (Ni…”
BackgroundInfluentialSelf-citationInflammaging decreases adaptive and innate immune responses in mice and humans
Frasca, D., & Blomberg, B. B. (2016) · Biogerontology · doi:10.1007/s10522-015-9578-8 · Cited by 357
“It has been shown that human serum TNF-a levels negatively correlate with T cell function (Bryl et al. 2005, 2001; Parish et al. 2009).”
Tyagi, A. M., Srivastava, K., Mansoori, M. N., Trivedi, R., Chattopadhyay, N., & Singh, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044552 · Cited by 326
Reversible Senescence in Human CD4+CD45RA+CD27− Memory T Cells
Di Mitri, D., Azevedo, R. I., Henson, S. M., Libri, V., Riddell, N. E., Macaulay, R., Kipling, D., Soares, M. V. D., Battistini, L., & Akbar, A. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100978 · Cited by 231
Thewissen, M., Somers, V., Hellings, N., Fraussen, J., Damoiseaux, J., & Stinissen, P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.6514 · Cited by 201
“the frequency of CD4 CD28 T lymphocytes (19, 20).”
BackgroundBrzustewicz, E., & Bryl, E. (2015) · Cytokine · doi:10.1016/j.cyto.2015.08.260 · Cited by 196
Self-citationCellular senescence impact on immune cell fate and function
Vicente, R., Mausset-Bonnefont, A.-L., Jorgensen, C., Louis-Plence, P., & Brondello, J.-M. (2016) · Aging Cell · doi:10.1111/acel.12455 · Cited by 151
“Thus, anti-TNF-a therapy in patients with RA was used to restore telomerase expression in T lymphocytes, thus delaying RA-induced premature T senescence (Bryl et al., 2005).”
MethodPathogenic features of CD4+CD28– T cells in immune disorders
Broux, B., Markovic-Plese, S., Stinissen, P., & Hellings, N. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.06.003 · Cited by 131
Broadley, I., Pera, A., Morrow, G., Davies, K. A., & Kern, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00195 · Cited by 103
Targeting T cells to treat atherosclerosis: odyssey from bench to bedside
Bullenkamp, J., Dinkla, S., Kaski, J. C., & Dumitriu, I. E. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw001 · Cited by 38
Impact of Age-, Cancer- and Treatment-Driven Inflammation on T Cell Function and Immunotherapy
Quinn, K. M., Kartikasari, A. E. R., Cooke, R. E., Koldej, R. M., Ritchie, D. S., & Plebanski, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0520-466r · Cited by 31
Apoptotic effects of antilymphocyte globulins on human pro-inflammatory CD4+CD28- T-cells
Duftner, C., Dejaco, C., Hengster, P., Bijuklic, K., Joannidis, M., Margreiter, R., & Schirmer, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033939 · Cited by 23
“however, up to now, only 33–36% decrement of peripheral CD4CD28 T-cells was observed after treatment with the antitumor necrosis factor-a (TNF-a) antibody, infliximab [37–40].”
Background
Metadata
- Authors
- Bryl, E., Vallejo, A. N., Matteson, E. L., Witkowski, J. M., Weyand, C. M., & Goronzy, J. J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-09-30
- Volume
- 52
- Issue
- 10
- Pages
- 2996-3003
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2091989980
- Cited by
- 142
- References
- 7
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.